186 related articles for article (PubMed ID: 9511068)
1. In-vitro activity of quinupristin/dalfopristin compared with other widely used antibiotics against strains isolated from patients with endocarditis.
Mouton JW; Endtz HP; den Hollander JG; van den Braak N; Verbrugh HA
J Antimicrob Chemother; 1997 May; 39 Suppl A():75-80. PubMed ID: 9511068
[TBL] [Abstract][Full Text] [Related]
2. Comparative in-vitro activities of quinupristin-dalfopristin against Gram-positive bloodstream isolates.
Schouten MA; Hoogkamp-Korstanje JA
J Antimicrob Chemother; 1997 Aug; 40(2):213-9. PubMed ID: 9301986
[TBL] [Abstract][Full Text] [Related]
3. In-vitro and in-vivo antibacterial activity of quinupristin/dalfopristin.
Bouanchaud DH
J Antimicrob Chemother; 1997 May; 39 Suppl A():15-21. PubMed ID: 9511057
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity and post-antibiotic effect of quinupristin/dalfopristin (Synercid).
Ling TK; Fung KS; Cheng AF
Chemotherapy; 2001; 47(4):243-9. PubMed ID: 11399860
[TBL] [Abstract][Full Text] [Related]
5. Antimicrobial susceptibility of quinupristin/dalfopristin tested against gram-positive cocci from Latin America: results from the global SMART (GSMART) surveillance study.
Sader HS; Jones RN; Ballow CH; Biedenbach DJ; Cered RF;
Braz J Infect Dis; 2001 Feb; 5(1):21-31. PubMed ID: 11290311
[TBL] [Abstract][Full Text] [Related]
6. In vitro activities of eight macrolide antibiotics and RP-59500 (quinupristin-dalfopristin) against viridans group streptococci isolated from blood of neutropenic cancer patients.
Alcaide F; Carratala J; Liñares J; Gudiol F; Martin R
Antimicrob Agents Chemother; 1996 Sep; 40(9):2117-20. PubMed ID: 8878591
[TBL] [Abstract][Full Text] [Related]
7. In vitro activity of quinupristin/dalfopristin against gram-positive bacteria Haemophilus influenzae and Branhamella catarrhalis in Taiwan.
Wang FD; Lin ML; Liu CY
Zhonghua Yi Xue Za Zhi (Taipei); 2000 Jun; 63(6):433-9. PubMed ID: 10925532
[TBL] [Abstract][Full Text] [Related]
8. Development of provisional disc diffusion breakpoints for testing quinupristin/dalfopristin.
Tenover FC; Baker CN
J Antimicrob Chemother; 1997 May; 39 Suppl A():81-5. PubMed ID: 9511069
[TBL] [Abstract][Full Text] [Related]
9. Activity of quinupristin/dalfopristin against gram-positive bacteria: clinical applications and therapeutic potential.
Rubinstein E; Bompart F
J Antimicrob Chemother; 1997 May; 39 Suppl A():139-43. PubMed ID: 9511078
[TBL] [Abstract][Full Text] [Related]
10. In vitro activity of quinupristin/dalfopristin, RP59500, against gram-positive clinical isolates.
Qadri SM; Ueno Y; Abu Mostafa FM; Halim M
Chemotherapy; 1997; 43(2):94-9. PubMed ID: 9084917
[TBL] [Abstract][Full Text] [Related]
11. Antimicrobial activity of quinupristin/dalfopristin, a new injectable streptogramin with a wide Gram-positive spectrum.
Speciale A; La Ferla K; Caccamo F; Nicoletti G
Int J Antimicrob Agents; 1999 Sep; 13(1):21-8. PubMed ID: 10563401
[TBL] [Abstract][Full Text] [Related]
12. Quinupristin/dalfopristin: a review of its use in the management of serious gram-positive infections.
Lamb HM; Figgitt DP; Faulds D
Drugs; 1999 Dec; 58(6):1061-97. PubMed ID: 10651391
[TBL] [Abstract][Full Text] [Related]
13. In vitro activity of quinupristin/dalfopristin against erythromycin-susceptible and erythromycin-resistant Streptococcus pneumoniae.
Reinert RR; Kresken M; Mechery V; Lemperle M; Lütticken R
Eur J Clin Microbiol Infect Dis; 1998 Sep; 17(9):662-5. PubMed ID: 9832271
[TBL] [Abstract][Full Text] [Related]
14. Quinupristin-dalfopristin resistance among gram-positive bacteria in Taiwan.
Luh KT; Hsueh PR; Teng LJ; Pan HJ; Chen YC; Lu JJ; Wu JJ; Ho SW
Antimicrob Agents Chemother; 2000 Dec; 44(12):3374-80. PubMed ID: 11083643
[TBL] [Abstract][Full Text] [Related]
15. Antimicrobial activity of quinupristin-dalfopristin (RP 59500, Synercid) tested against over 28,000 recent clinical isolates from 200 medical centers in the United States and Canada.
Jones RN; Ballow CH; Biedenbach DJ; Deinhart JA; Schentag JJ
Diagn Microbiol Infect Dis; 1998 Jul; 31(3):437-51. PubMed ID: 9635235
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro activities of daptomycin, linezolid, and quinupristin/dalfopristin against Gram-positive bacterial isolates from a large cancer center.
Smith PF; Booker BM; Ogundele AB; Kelchin P
Diagn Microbiol Infect Dis; 2005 Jul; 52(3):255-9. PubMed ID: 15935606
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of quinupristin/dalfopristin against clinical isolates of common gram-positive bacteria in Taiwan.
Chang SC; Fang CT; Hsueh PR; Luh KT; Hsieh WC
Diagn Microbiol Infect Dis; 1999 Apr; 33(4):299-303. PubMed ID: 10212757
[TBL] [Abstract][Full Text] [Related]
18. Role of quinupristin/dalfopristin in the treatment of Gram-positive nosocomial infections in haematological or oncological patients.
Klastersky J
Cancer Treat Rev; 2003 Oct; 29(5):431-40. PubMed ID: 12972361
[TBL] [Abstract][Full Text] [Related]
19. Quinupristin-dalfopristin (RP 59500): an injectable streptogramin combination.
Griswold MW; Lomaestro BM; Briceland LL
Am J Health Syst Pharm; 1996 Sep; 53(17):2045-53. PubMed ID: 8870891
[TBL] [Abstract][Full Text] [Related]
20. Antibacterial activity of quinupristin/dalfopristin. Rationale for clinical use.
Finch RG
Drugs; 1996; 51 Suppl 1():31-7. PubMed ID: 8724814
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
